home / stock / akro / akro news

AKRO News and Press, Akero Therapeutics Inc. From 08/04/21

Stock Information
Company Name: Akero Therapeutics Inc.
Stock Symbol: AKRO
Market: NYSE
Website: akerotx.com
Menu
AKRO AKRO Quote AKRO Short AKRO News AKRO Articles AKRO Message Board
Get AKRO Alerts

News, Short Squeeze, Breakout and More Instantly...
AKRO - Fate Therapeutics Appoints Yuan Xu to its Board of Directors

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced the appointment of Yuan Xu, Ph.D., to its Board of Directors as an ...
AKRO - 89bio and Viking Therapeutics become BTIG's top picks in NASH space

BTIG has resumed coverage of 89bio (ETNB -0.1%) and Viking Therapeutics (VKTX +4.0%) categorizing the clinical-stage biotech companies as its top picks among the developers in the field of nonalcoholic steatohepatitis (NASH). The analyst Justin Zelin thinks that the lead candidates from the t...

AKRO - Akero Therapeutics Appoints Judy Chou, Ph.D., to its Board of Directors

SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced the appointment of Judy Chou, Ph.D...

AKRO - Akero Therapeutics' efruxifermin meets primary endpoint in mid-stage NASH trial

Akero Therapeutics ([[AKRO]] -1.4%) announces that its non-alcoholic steatohepatitis ((NASH)) treatment efruxifermin ((EFX)) met its primary endpoint of reducing liver fat in a mid-stage trial.The company announced that the full results of the main portion of its Phas...
AKRO - Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of Treatment

SOUTH SAN FRANCISCO, Calif., July 08, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that full results of the main portion o...

AKRO - Akero Therapeutics Presents at the American Diabetes Association's 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-

SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced additional analyses from its Phase 2a B...

AKRO - Akero Therapeutics Presents Analyses at the 2021 International Liver Congress Showing Normalization of Liver Fat Substantially Reduced Markers of Liver Injury and Fibrosis, and Greatly Increased Probability of Resolving NASH

SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced additional analyses from its Phase...
AKRO - Akero Therapeutics to Present Efruxifermin (EFX) Results Showing Histologic Improvement in EFX-Treated F4 Cirrhotic Patients as a Late-Breaker Oral Presentation at the 2021 International Liver Congress

SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that it will present results from the C...

AKRO - Akero Therapeutics to Present at the Jefferies Virtual Healthcare Conference

SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that members of the management team will present at th...

AKRO - Akero Therapeutics: A NASH Pureplay With Differentiated Mid Stage Data

AKRO has produced highly competitive phase 2a data and has a phase 2b running with data later this year. NASH is a vast market and AKRO looks like the real deal in the space. The company is adequately financed for the next 18 months at the least. For further details see: ...
Previous 10 Next 10